Antibody Conjugates-Recent Advances and Future Innovations
Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to traditional small molecules across the industry....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/9/1/2 |
| _version_ | 1818388815462531072 |
|---|---|
| author | Donmienne Leung Jacqueline M. Wurst Tao Liu Ruben M. Martinez Amita Datta-Mannan Yiqing Feng |
| author_facet | Donmienne Leung Jacqueline M. Wurst Tao Liu Ruben M. Martinez Amita Datta-Mannan Yiqing Feng |
| author_sort | Donmienne Leung |
| collection | DOAJ |
| description | Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to traditional small molecules across the industry. However, protein therapeutics cannot drug targets intracellularly and are limited to soluble and cell-surface antigens. Tremendous strides have been made in antibody discovery, protein engineering, formulation, and delivery devices. These advances continue to push the boundaries of biologics to enable antibody conjugates to take advantage of the target specificity and long half-life from an antibody, while delivering highly potent small molecule drugs. While the “magic bullet” concept produced the first wave of antibody conjugates, these entities were met with limited clinical success. This review summarizes the advances and challenges in the field to date with emphasis on antibody conjugation, linker-payload chemistry, novel payload classes, absorption, distribution, metabolism, and excretion (ADME), and product developability. We discuss lessons learned in the development of oncology antibody conjugates and look towards future innovations enabling other therapeutic indications. |
| first_indexed | 2024-12-14T04:31:50Z |
| format | Article |
| id | doaj.art-fdfc6332ec064146af9777409f73155a |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-12-14T04:31:50Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-fdfc6332ec064146af9777409f73155a2022-12-21T23:17:04ZengMDPI AGAntibodies2073-44682020-01-0191210.3390/antib9010002antib9010002Antibody Conjugates-Recent Advances and Future InnovationsDonmienne Leung0Jacqueline M. Wurst1Tao Liu2Ruben M. Martinez3Amita Datta-Mannan4Yiqing Feng5Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USADiscovery Chemistry and Research Technology, Lilly Research Laboratories, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USADiscovery Chemistry and Research Technology, Lilly Research Laboratories, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USADiscovery Chemistry and Research Technology, Lilly Research Laboratories, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USAExploratory Medicine & Pharmacology, Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46225, USABiotechnology Discovery Research, Lilly Research Laboratories, Lilly Technology Center North, Eli Lilly and Company, Indianapolis, IN 46221, USAMonoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to traditional small molecules across the industry. However, protein therapeutics cannot drug targets intracellularly and are limited to soluble and cell-surface antigens. Tremendous strides have been made in antibody discovery, protein engineering, formulation, and delivery devices. These advances continue to push the boundaries of biologics to enable antibody conjugates to take advantage of the target specificity and long half-life from an antibody, while delivering highly potent small molecule drugs. While the “magic bullet” concept produced the first wave of antibody conjugates, these entities were met with limited clinical success. This review summarizes the advances and challenges in the field to date with emphasis on antibody conjugation, linker-payload chemistry, novel payload classes, absorption, distribution, metabolism, and excretion (ADME), and product developability. We discuss lessons learned in the development of oncology antibody conjugates and look towards future innovations enabling other therapeutic indications.https://www.mdpi.com/2073-4468/9/1/2antibodiessite-specific conjugationbioconjugatesadcantibody-drug conjugatespayloadslinkersnucleic acidsadmedevelopabilityformulation |
| spellingShingle | Donmienne Leung Jacqueline M. Wurst Tao Liu Ruben M. Martinez Amita Datta-Mannan Yiqing Feng Antibody Conjugates-Recent Advances and Future Innovations Antibodies antibodies site-specific conjugation bioconjugates adc antibody-drug conjugates payloads linkers nucleic acids adme developability formulation |
| title | Antibody Conjugates-Recent Advances and Future Innovations |
| title_full | Antibody Conjugates-Recent Advances and Future Innovations |
| title_fullStr | Antibody Conjugates-Recent Advances and Future Innovations |
| title_full_unstemmed | Antibody Conjugates-Recent Advances and Future Innovations |
| title_short | Antibody Conjugates-Recent Advances and Future Innovations |
| title_sort | antibody conjugates recent advances and future innovations |
| topic | antibodies site-specific conjugation bioconjugates adc antibody-drug conjugates payloads linkers nucleic acids adme developability formulation |
| url | https://www.mdpi.com/2073-4468/9/1/2 |
| work_keys_str_mv | AT donmienneleung antibodyconjugatesrecentadvancesandfutureinnovations AT jacquelinemwurst antibodyconjugatesrecentadvancesandfutureinnovations AT taoliu antibodyconjugatesrecentadvancesandfutureinnovations AT rubenmmartinez antibodyconjugatesrecentadvancesandfutureinnovations AT amitadattamannan antibodyconjugatesrecentadvancesandfutureinnovations AT yiqingfeng antibodyconjugatesrecentadvancesandfutureinnovations |